Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled Trial

Efficacy, Safety and Acceptability of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023125

Enrollment

Registered

2020-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intravenous Iron And Oral Iron: Patients with Hemoglobin between 8-10gm/dl, 36-48 hours after delivery. Group A will be treated with Intravenous Iron . Group B will be treated with Tabl

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Hemoglobin between 8-10gm/dl, 36-48 hours after delivery. Group A will be treated with Intravenous Iron . Group B will be treated with Tablet Iron.

Exclusion criteria

Exclusion criteria: Peripartum Blood Transfusion Intolerance To Iron Derivatives Clotting disorders Patients with Anemia other than that caused by blood loss secondary to delivery and iron deficiency anemia.

Design outcomes

Primary

Measure	Time frame
To identify the efficacy of Intravenous Iron therapy compared with Oral Iron for treating Postpartum anemiaTimepoint: 36-48 Hours after delivery 2 Weeks and 6 Weeks Postpartum period	—

Secondary

Measure	Time frame
To find out if there are adverse drug reaction to Intravenous Ferric carboxy maltose as treatment for Postpartum anemia To find out the acceptability of intravenous iron ( ferric carboxy maltose) therapy for postpartum anemiaTimepoint: 36-48 Hours after delivery 2 Weeks and 6 Weeks Postpartum period	—

Countries

India

Contacts

Public ContactDr VPPaily

rajagirihospital

vppaily@gmail.com9447633707

Outcome results